Short Interest in Applied DNA Sciences, Inc. (NASDAQ:APDN) Decreases By 92.2%

Applied DNA Sciences, Inc. (NASDAQ:APDN) was the target of a significant decline in short interest in March. As of March 15th, there was short interest totalling 233,100 shares, a decline of 92.2% from the February 28th total of 3,000,000 shares. Currently, 22.6% of the company’s stock are sold short. Based on an average trading volume of 670,200 shares, the days-to-cover ratio is presently 0.3 days.

Institutional Trading of Applied DNA Sciences

Several institutional investors and hedge funds have recently bought and sold shares of APDN. Millennium Management LLC bought a new stake in shares of Applied DNA Sciences in the 4th quarter valued at approximately $28,000. Connective Capital Management LLC bought a new position in Applied DNA Sciences during the fourth quarter worth $36,000. Jane Street Group LLC acquired a new position in Applied DNA Sciences in the third quarter worth $48,000. Finally, Geode Capital Management LLC increased its stake in Applied DNA Sciences by 291.1% during the fourth quarter. Geode Capital Management LLC now owns 417,485 shares of the technology company’s stock valued at $85,000 after purchasing an additional 310,749 shares during the last quarter. Institutional investors and hedge funds own 22.22% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, StockNews.com began coverage on Applied DNA Sciences in a research note on Monday, March 17th. They set a “sell” rating for the company.

Applied DNA Sciences Price Performance

APDN opened at $2.06 on Thursday. Applied DNA Sciences has a 12-month low of $1.67 and a 12-month high of $460.00. The stock has a market capitalization of $2.27 million, a PE ratio of -0.36 and a beta of 0.43. The firm’s fifty day moving average price is $6.90 and its 200 day moving average price is $15.25.

Applied DNA Sciences (NASDAQ:APDN) last issued its earnings results on Thursday, February 13th. The technology company reported ($28.00) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($16.00) by ($12.00). Applied DNA Sciences had a negative net margin of 228.12% and a negative return on equity of 101.57%. On average, equities research analysts forecast that Applied DNA Sciences will post -0.87 earnings per share for the current fiscal year.

Applied DNA Sciences Company Profile

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.